April 14, 2011

Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease

- Alemtuzumab Seen to Improve Low-Contrast Vision -
- Data Presented at 63rd Annual Meeting of the American Academy of Neurology -

 

Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
- Alemtuzumab Seen to Improve Low-Contrast Vision -
- Data Presented at 63rd Annual Meeting of the American Academy of Neurology -

Paris, France – April 14, 2011 – Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), reported today additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug. The data were presented at the American Academy of Neurology’s 63rd Annual Meeting.